Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UDI Final Rule Listed For July Release In HHS Regulatory Agenda

This article was originally published in The Gray Sheet

Executive Summary

The UDI final rule is among 11 device-focused proposed and final regulations included in the HHS unified agenda of regulations planned through early 2014, and it is likely the most closely watched of the group by industry.

You may also be interested in...



FDA Issues UDI Final Rule, Removes Direct Marking Requirement For Implants

The long-awaited unique device identifier final rule is intended to help FDA, device companies and health care providers track medical devices. The rule addresses many of industry’s concerns with FDA’s initial proposal and was met with general support by companies.

Regulatory Briefs: OMB Updates On UDI, eMDR Rule; Circ Panel Scheduled

Hospital groups meet with OMB on UDI rule. Electronic Medical Device Reporting final rule reaches OMB. More regulatory news.

Ortho-tag Inc.

There are times when joint replacement patients and their treating physicians need to quickly identify what kind of orthopedic device has been implanted, but the information isn’t always easy to find. Ortho-tag Inc. aims to change that with a tag that turns orthopedic implants into devices capable of communicating important information to treating physicians directly from the patient.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel